Welcome to our dedicated page for Blueprint Medicines news (Ticker: BPMC), a resource for investors and traders seeking the latest updates and insights on Blueprint Medicines stock.
Blueprint Medicines Corporation (BPMC) pioneers targeted kinase therapies for genetically defined cancers and rare disorders. This dedicated news hub provides stakeholders with comprehensive updates on the company's scientific advancements, regulatory progress, and strategic initiatives.
Access verified information about clinical trial results, FDA submissions, partnership announcements, and financial disclosures. Our curated collection ensures efficient tracking of BPMC's precision medicine developments without promotional bias.
Key focus areas include oncology pipeline updates, rare disease therapy approvals, and research collaborations. Content is rigorously organized to help users quickly identify material events impacting the company's trajectory in genomic medicine.
Bookmark this page for streamlined monitoring of Blueprint Medicines' progress in developing therapies that address abnormal kinase activity through innovative small molecule inhibitors. Check regularly for authoritative reporting on developments directly from corporate communications and validated sources.
Blueprint Medicines (NASDAQ: BPMC) has announced that it will host a live conference call and webcast on Wednesday, October 30, 2024, at 8:00 a.m. ET to report its third quarter 2024 financial results and provide a corporate update. Interested parties can access the live conference call by dialing 833-470-1428 (domestic) or 404-975-4839 (international) and referring to conference ID 387547.
A webcast of the call will also be available under the 'Events and Presentations' section of the company's Investors & Media webpage. The archived webcast will be accessible on Blueprint Medicines' website approximately two hours after the conference call and will remain available for 30 days following the call.
Blueprint Medicines (NASDAQ: BPMC) has announced its participation in two upcoming virtual investor conferences. The company will present at the Stifel 2024 Immunology and Inflammation Virtual Summit on Tuesday, September 17, 2024, at 2:00 p.m. ET, and at TD Cowen's Chronic Urticaria Summit on Friday, September 20, 2024, at 11:00 a.m. ET.
Investors and interested parties can access live webcasts of both presentations through the Investors & Media section of Blueprint Medicines' website. Replays of the webcasts will be available on the company's website for 30 days following each presentation, providing an opportunity for those unable to attend the live events to catch up on the information shared.
The Schall Law Firm is investigating potential securities law violations by Blueprint Medicines (NASDAQ: BPMC). The investigation centers on whether Blueprint issued false or misleading statements to investors. On August 17, 2022, Blueprint announced top-line results from Part 2 of its PIONEER clinical trial for AYVAKIT® (avapritinib). The company revealed that the absolute improvement in symptom score decreased from 19.7 in Part 1 to 15.6 in Part 2. This news caused Blueprint's stock to fall by 10% on the same day.
Shareholders who suffered losses are encouraged to contact the Schall Law Firm to discuss their rights. The firm specializes in securities class action lawsuits and shareholder rights litigation. It's important to note that the class in this case has not yet been certified, and affected shareholders are not currently represented by an attorney unless they take action.
Blueprint Medicines reported strong Q2 2024 results, with AYVAKIT net product revenues of $114.1 million, representing over 185% year-over-year growth. The company raised its full-year 2024 AYVAKIT revenue guidance to $435-$450 million, up from $390-$410 million. Total revenues were $138.2 million for Q2 2024.
Key highlights include:
- Initiated Phase 1 healthy volunteer trial of wild-type KIT inhibitor BLU-808
- Presented positive combination safety data for CDK2 inhibitor BLU-222
- Expects to initiate registration-enabling HARBOR Part 2 study of elenestinib in indolent systemic mastocytosis later this year
Blueprint Medicines reported a net loss of $50.0 million for Q2 2024, compared to $132.8 million in Q2 2023. The company's cash position as of June 30, 2024, was $868.5 million.
Blueprint Medicines (NASDAQ: BPMC) has announced its plans to report second quarter 2024 financial results on Thursday, August 1, 2024. The company will host a live conference call and webcast at 8:00 a.m. ET to present the results and provide a corporate update. Interested parties can access the call by dialing 833-470-1428 (domestic) or 404-975-4839 (international) with the conference ID 299779. A webcast will also be available on the company's website under the Investors & Media section. The archived webcast will remain accessible for 30 days following the call.
Blueprint Medicines (NASDAQ: BPMC) announced presentations at the EAACI and EHA annual meetings showcasing the durable clinical benefits of AYVAKIT® (avapritinib) for systemic mastocytosis (SM). Seven presentations, including four oral sessions, will highlight data across different studies like PIONEER, PATHFINDER, and PRISM. Key findings include sustained efficacy and safety of AYVAKIT, improved quality of life for patients, and significant overall response rates. The PRISM survey underscores the substantial impact of SM on patients' lives, emphasizing the urgency to diagnose and treat the condition. The presentations will be available on the company’s website.
Blueprint Medicines announced updated Phase 1 data for their CDK2 inhibitor, BLU-222, in combination with ribociclib and fulvestrant, for HR+/HER2- breast cancer. The study showed BLU-222 was well-tolerated with no dose-limiting toxicities. Updated data indicate significant biomarker reductions correlated with BLU-222 exposure. Early results suggest clinical activity, including one unconfirmed partial response. Detailed findings will be presented at the 2024 ASCO Annual Meeting.
Blueprint Medicines announced the granting of non-qualified stock options and restricted stock units to new employees under their 2020 Inducement Plan. The options have an exercise price of $94.86 per share and will vest over time based on continued employment.
Blueprint Medicines reported strong first quarter 2024 results, generating $92.5 million in AYVAKIT net product revenues and raising full-year revenue guidance to $390-$410 million. The company is on track to submit an IND for BLU-808 in Q2 to strengthen its presence in allergy and inflammation. Blueprint Medicines continues to advance its pipeline, with key developments in mast cell disorders and HR+/HER2- breast cancer. Financially, the company anticipates growth in global product revenues, decreased operating expenses, and a strong cash position.
FAQ
What is the current stock price of Blueprint Medicines (BPMC)?
What is the market cap of Blueprint Medicines (BPMC)?
